"Repeal, Replace, or Rebrand?", find Frost & Sullivan's Visionary Healthcare team's perspectives on what is in store for main industry stakeholders
SANTA CLARA, California, Dec. 14, 2016 /PRNewswire/ -- Translating bold campaign trail claims of "repeal and replace" into legislative action can often be challenging with any established bill, let alone one as complex as the Affordable Care Act (ACA). As the ACA is built on a number of interlocking provisions and funding mechanisms, any unilateral actions proposed by the new administration must carefully take into consideration any potential secondary repercussions.
"Initially, rather than outright repeal, the Trump administration and Congress could simply defund certain aspects of the bill, as well as choose to not enforce certain punitive aspects of the bill," said Frost & Sullivan Visionary Healthcare Industry Analyst Kamaljit Behera. "Many of those provisions include most prominently mandates on health insurance coverage for individuals and large employers, as well as taxes aimed at high premium insurance plans, and medical device manufacturers.''
A recent article from Frost & Sullivan's Visionary Healthcare Growth Partnership Service program looks at the possibilities unfolding over the next 100 days for the healthcare industry. It also explores the opportunities and challenges in sectors such as pharma & biopharma, medical technologies, diagnostics, healthcare IT, providers (hospitals), payers (health insurance), and consumers.
As changes transpire and developments unfold, Frost & Sullivan's experts are working with industry leading organizations and companies to help them understand any direct implications of the US presidential election and develop appropriate strategies. Register today for a Growth Strategy Dialogue, a complimentary interactive briefing with Frost & Sullivan's thought leaders, to understand the challenges, find the solutions and uncover your next growth opportunity. Click here or send an email to Mariana Fernandez (email@example.com).
President elect Trump appointed Tom Price and Seema Verma, respectively to lead the departments of Health & Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS). As he seems inclined to focus on big picture themes and delegate execution to his cabinet members, these appointees might have more authority to implement changes than any of their predecessors.
As a former practicing orthopedic surgeon, Congressman Tom Price is expected to fight against measures that restrict the autonomy of physicians in determining the appropriate course of care for their patients. This notion creates a degree of uncertainty around the roll out of the Medicare Access and CHIP Reauthorization Act (MACRA) legislation, a bill that fundamentally changes how physicians are compensated when supporting Medicare beneficiaries.
Announced initiatives of the new administration when considered in conjunction with bi-partisan passage of the 21st Century Cures Act, which dramatically modifies how new therapeutics & technologies are regulated by the Food and Drug Administration (FDA), will make 2017 a true game changing year for the industry.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion
Corporate Communications – North America
P: +54 11 4778 3540
F: +54 11 4777 0071
SOURCE Frost & Sullivan